TCR2 Therapeutics shares rise after cancer drug trial update

TCR2 Therapeutics

08/08/2019 16:24

** Drug developer's shares  TCRR.O  up 3.4% at $15.82     
    ** Co says has started early stage trial of its drug TC-210
to treat patients with different types of cancer, including lung
and ovarian cancer       
    ** Initial data expected late 2019 or early 2020
    ** Co says will file application to begin human testing of
its drug TC-110 in patients with blood cancer late this year 
    ** TCRR ended Q2 with $180.7 mln in cash; says has runway
into 2022 
    ** SVB Leerink analyst Jonathan Chang says pipeline update
was in line with expectations
    ** Co also posts Q2 net loss of $11.1 mln, versus $6.2 mln
last year, as R&D expenses rose in the quarter 
    ** "We maintain a positive long-term view of the stock based
on the experienced management team and potentially
transformative platform with broad potential therapeutic
applicability," Chang says

 (Reporting by Tamara Mathias in Bengaluru)
 ((Tamara.Mathias@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 1208;))